Clinical Trials

    Showing 1 - 5 of 5 Parkinson's Disease

    A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

    Status: Open Not Enrolling

    Investigator: William Ondo

    Study Coordinator: Nijah Russell

    Phone: 346.238.2287

    The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts.This study will be held in approximately 5-6 study sites in North Amer... Read more >

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)

    Status: Enrolling

    Investigator: William Ondo

    Study Coordinator: Daniel Arnaud Dominguez

    Phone: 346.356.3635

    The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.... Read more >

    A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

    Status: Enrolling

    Investigator: Stanley Appel

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neurolog... Read more >

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Status: Open Not Enrolling

    Investigator: Joseph Imbs

    Study Coordinator: Daniel Arnaud Dominguez

    Phone: 346.356.3635

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).... Read more >

    Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States

    Status: Open Not Enrolling

    Investigator: Andrew Billnitzer

    Study Coordinator: Daniel Arnaud Dominguez

    Phone: 346.356.3635

    Real-World Participants' Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease. This observational study includes an Enrollment... Read more >